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Brief Report
The Relation of Plasmacytoid Dendritic Cells (pDCs)
and Regulatory T-Cells (Tregs) with HPV Persistence
in HIV-Infected and HIV-Uninfected Women
Howard D. Strickler,1 Jeffrey Martinson,2 Seema Desai,2 Xianhong Xie,1 Robert D. Burk,1 Kathryn Anastos,1
L. Stewart Massad,3 Howard Minkoff,4 Xiaonan Xue,1 Gypsyamber D’Souza,5 Alexandra M. Levine,6
Christine Colie,7 D. Heather Watts,8 Joel M. Palefsky,9 and Alan Landay2
Abstract
Other than CD4+ count, the immunologic factors that underlie the relationship of HIV/AIDS with persistent
oncogenic HPV (oncHPV) and cervical cancer are not well understood. Plasmacytoid dendritic cells (pDCs) and
regulatory T-cells (Tregs) are of particular interest. pDCs have both effector and antigen presenting activity and,
in HIV-positive patients, low pDC levels are associated with opportunistic infections. Tregs downregulate
immune responses, and are present at high levels in HIV-positives. The current pilot study shows for the first
time that low pDC and high Treg levels may be significantly associated with oncHPV persistence in both HIV-
positive and HIV-negative women. Larger studies are now warranted.
Introduction
Plasmacytoid dendritic cells (pDC) and regulatoryT-cells (Treg) may play an important role in HIV
pathogenesis and disease progression. However, their role
in the control of human papillomavirus (HPV), the viral
cause of cervical cancer, an AIDS-defining malignancy, has
not been carefully studied. pDCs are of particular interest,
since diminished pDC count and function are strongly
predictive of opportunistic infections in HIV-positive pa-
tients, independent of CD4 + T-cell count (19–21), and
imiquimod, a topically applied toll-like receptor (TLR)
agonist used to treat HPV-associated warts, may partly act
through activation of local pDCs (6). pDCs are unique in
that they bridge the innate and the adaptive immune sys-
tems (8,11). pDCs exist in the circulation and tissues as
effector cells of the innate immune system that secrete in-
terferon (IFN)-a and other type I IFNs upon stimulation by
microbial pathogens. However, they are also precursor
cells, and following antigen interaction. they are thought to
mature and differentiate into dendritic cells (professional
antigen presenting cells) that are critical in initiating the
adaptive immune response through cognate interaction
with CD4 + T-cells (7). In vitro data show that pDCs can
respond to HPV antigens (10).
Tregs are involved in virtually all stages of the adaptive
immune response (see Fazekas de St Groth and Landay,
2008, for review) (5). This includes downregulation of
self-reactive immune cells, as well as the downregulation
of T cell responses to foreign antigens at the expansion and
effector stages. The mechanisms of action, though, remain
somewhat uncertain. It has been suggested that Treg ac-
tivity may play a role in the establishment of the HIV
carrier state (3). The number of Tregs increases in the gut
during HIV infection, and high Treg ratios have been re-
ported in patients with low CD4 + and high HIV RNA
levels (3,9). A small but growing literature suggests that
high levels of Tregs and cytokines associated with Treg
activity are more common in patients with HPV-related
cervical lesions (13–15,18).
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To our knowledge, however, no studies of oncogenic
HPV (oncHPV) infection and pDC levels have been re-
ported, nor have the few prior studies of Tregs and HPV
involved HIV-positive women despite the known abnor-
malities of Treg and pDC levels and function among HIV-
positive patients. Therefore, we conducted a small pilot
study to assess the relationship between pDC and Treg
levels in HIV-positive women and oncHPV persistence
(versus clearance). A smaller number of HIV-negative
women were included as an additional comparison group
and to obtain normal values.
Methods
Subjects and specimens
Data and specimens were obtained from the Women’s In-
teragency HIV Study (WIHS), a large prospective cohort in-
vestigation. A detailed summary of the WIHS and its methods
has been previously reported. Briefly, HIV-positive (n= 2543)
and at-risk HIV-negative (n= 895) women were followed
semiannually with clinical visits that involved a full gyneco-
logic examination, including collection of a cervicovaginal
lavage (CVL) for HPV DNA testing. Blood specimens were
also collected and tested for total CD4+ T-cell count and HIV
RNA levels in laboratories participating in the DAIDS Quality
Assurance Program. Additional whole blood was collected in
sodium heparin-coated tubes and used to separate and cryo-
preserve peripheral blood mononuclear cells (PBMCs) using
standard, previously described methods (17).
For the current pilot study, we used stratified random sam-
pling to select 19 ‘‘oncHPV persisters’’ and a comparison
group of 19 ‘‘oncHPV clearers.’’ We defined an oncHPV
persister as a woman who tested positive for at least one
oncHPV type, whether a prevalent or incident infection, who
then continued to test positive for one or more of the same
oncHPV types for ‡ 1.5 years (four semi-annual visits). An
oncHPV clearer was defined as a woman who tested positive
for at least one oncHPV type at the time of blood collection but
had no oncHPV at all detected at the next 6-month clinic visit.
We limited the selection ofHIV-positivewomen to thosewith a
CD4+ > 350/lL, since it was felt that the contribution of pDC
and Treg levels to risk of persistent HPV might be difficult to
discern in women with a very low CD4 count. All women had
to have at least 2 years of follow-up (four visits plus baseline
visit) with no more than one missing visit. PBMC specimens
were available from 16 of the 19 oncHPV persisters (13 HIV-
positive with a CD4+ > 350/lL and 3 HIV-negative women)
and 15 of the 19 oncHPV clearers (10 HIV-positive with a
CD4+ > 350/lL and 5 HIV-negative women).
HPV testing
HPV DNA was detected in CVL specimens using a well-
established polymerase chain reaction (PCR) assay that
employed MY09/MY11/HMB01 consensus primers (16,22).
This assay has been shown to be highly sensitive and spe-
cific for the detection of > 40 different individual HPV types
(16). Amplification of a 268-base-pair fragment of the hu-
man b-globin gene was used as an internal control for
specimen adequacy. The HPV types considered oncogenic
were: 16/18/31/33/35/39/45/51/52/56/58/59/68, and all
other HPV were considered non-oncogenic.
Flow cytometry
Flow cytometry for pDCs and Tregs was conducted twice
for each subject, once using cryopreserved PBMC speci-
mens obtained at the first visit when oncHPV was detected
during this study, and again one year later. Briefly, the
cryopreserved PBMCs were removed from liquid nitrogen
(LN2) storage, thawed rapidly in a 37C water bath, washed,
and then incubated overnight at 37C 5% CO2 in RPMI
1640 media containing 10% heat-inactivated fetal bovine
serum (FBS). Following overnight incubation, the cells were
washed with Dulbecco’s PBS-(Ca+ +Mg+ + free) and stained
with Aqua Live/Dead cell stain kit (Invitrogen) to assess cell
viability. The PBMCs were then pre-treated with human Fc
block (Miltenyi Biotec) and stained for cell surface markers.
To assess pDCs, the PBMCs were incubated with the Lin1
FITC (BD), CD83 PE (Pharmingen), CD123 PerCP-Cy5.5
(Pharmingen), PDL-1 PE-Cy7 (eBioscience), CD11c AF700
(eBioscience), CD86 APC (Pharmingen), CCR7 eFluor780
(eBioscience), and HLA DR eFluor450 (eBioscience), washed
and resuspended in 2% formaldehyde-DPBS. To assess Tregs,
the PBMCs were stained with CD3 PacificBlue (Pharmingen),
CD4 PE-Texas Red (CalTag:Invitrogen), CD25 APC (BD),
CD45RO PE-Cy7 (BD), and PD-1 PE (eBioscience). Fol-
lowing surface staining, the Tregs were additionally washed,
fix/permeabilized with the FoxP3 Staining Buffer Set
(eBioscience), stained with FoxP3 FITC (eBioscience), and
CTLA-4 PE-Cy5 (Pharmingen), washed, and resuspended in
2% formaldehyde-DPBS. All stained cells were held at 4C
until acquired and analyzed within 24 h on a LSR2 flow
cytometer (BD) using FACS Diva 6.1.1 software (BD). The
analysis of flow cytometry data was performed after gating on
live (Aqua live dead) Lin1-yHLA DR+yCD123+ or
CD3+yCD4+yCD25+yFoxP3+ cells corresponding to
pDC (% of PBMC) or Tregs (% of CD4), respectively.
Statistical methods
Analyses of these immunologic data were conducted us-
ing t-tests (for continuous variables), chi-square (for cate-
gorical or ordinal variables), as well as logistic regression
models to conduct multivariate analyses. Both pDC% and
Treg% were log transformed to normalize their distribu-
tions. All statistical tests were two-sided, and p < 0.05 was
used to define statistical significance.
Results
Table 1 shows selected patient characteristics and labora-
tory data in oncHPV persisters and clearers, stratified by HIV
serostatus. Mean age was approximately 37 years in HIV-
positive and HIV-negative oncHPV persisters, and HIV-pos-
itive clearers, but was 33 years in HIV-negative clearers; a
moderate but statistically nonsignificant difference in this
small study. HAART use in HIV-positive women did not
significantly differ between persisters and clearers.
One of the selection criteria for HIV-positive women in
this study was a CD4 + > 350/lL, and neither the CD4 +
count ( p = 0.69) nor HIV viral load ( p = 0.27) differed be-
tween oncHPV persisters and clearers in univariate analyses
(Table 1). However, the percentage of CD4 + cells that were
found to be Tregs (Treg%) was significantly greater in HIV-
positive oncHPV persisters than clearers ( p= 0.02), and
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similar but nonsignificant Treg% results were found in HIV-
negative women ( p = 0.11). Conversely, the percentage of
PBMCs that were pDCs (pDC%) was nonsignificantly lower
in HIV-positive oncHPV persisters than clearers (p = 0.12),
and a similar but statistically significant difference was
observed in HIV-negative women ( p = 0.02).
Multivariate models controlling for age and HAART use
were conducted in HIV-positive women. However, given
the similarity of the univariate findings in HIV-positive and -
negative subjects, we also conducted multivariate models
that incorporated the data from both groups (Table 2). As in
the univariate analysis, the positive Treg% association
( p= 0.05) but not the negative pDC% association with
oncHPV persistence ( p= 0.22) was statistically significant in
models limited to HIV-positive women. In the combined
analysis of HIV-positive and HIV-negative subjects, how-
ever, the statistical significance of the Treg% ( p= 0.01) and
pDC% ( p= 0.03) associations with oncHPV persistence was
greater, while HIV-serostatus was not a significant factor
( p= 0.81 in Treg% model, as well as in the pDC% model).
The confidence intervals for the effects of pDC% and Treg%
were wide, though, reflecting the small size of this pilot
study, making it inappropriate to conduct models involving
multiple immunologic covariates (e.g., incorporating both
Treg% and pDC% in the same model).
Discussion
The results of this pilot study suggest that a high Treg% and
low pDC% are each associated with increased risk of oncHPV
persistence. These findings are consistent with growing un-
derstanding of the role of Tregs in downregulating host im-
mune response to pathogens (14), and the dual roles of pDCs
in the control of viral infection. pDCs are a-interferon-
secreting effector cells of the innate immune system with a
direct role in eliminating viral infection, but also act as antigen
presenting cells of the adaptive immune system, important in
the activation of T-cells (4,10). Furthermore, these associa-
tions were similar in both HIV-positive and HIV-negative
women. That is, while prior studies by our group and others
have shown that the risk of an oncHPV infection is several-
fold higher in HIV-positive than HIV-negative women, the
current data suggest that Treg% and pDC% are risk factors for
the persistence of oncHPV in both groups (22).
Our data showing a positive association of Treg% with risk
of oncHPV persistence are consistent with prior reports (13–
15,18), though the current pilot study is, to our knowledge,
the first to examine this relationship in HIV-positive women.
Thus, while the number of studies is still small, the consis-
tency of the findings regarding Tregs and oncHPV to date is
provocative. Conversely, the current study is the only one in
any population we are aware to examine the relation of
pDC% and oncHPV persistence, and these data must there-
fore be considered preliminary and await confirmation.
The findings of this study have potential clinical signifi-
cance since they suggest that modulating Tregs and PDCs
may be a useful strategy to help resolve persistent oncHPV
or oncHPV related neoplasia. It is noteworthy, therefore,
that imiquimod, a topically applied toll-like receptor agonist
used to treat HPV-related anogenital warts can activate
pDCs (6). Imiquimod is not recommended for treatment of
cervical lesions however, due to local cervical toxicity,
likely attributed to the pro-inflammatory milieu induced by
imiquimod. If confirmed, our results would suggest that
additional efforts to target pDCs may be warranted. This
may be especially relevant now that cervical oncHPV DNA
testing is a routine part of cervical cancer screening, since
physicians and their patients are often left with the dilemma
Table 1. Selected Baseline Patient Characteristics and Laboratory Test Results in HIV-Positive
and HIV-Negative Women who Tested Positive for Oncogenic HPV,














(N = 5) P value
Age – SD 37.6 – 7.9 37.3– 5.2 0.91 37.2 – 9.5 32.5 – 15.8 0.66
Total CD4 count (SE)a 540 (42.40)* 579 (47.72) 0.81 1244 (250.12)* 1441 (652.50) 0.84
Mean Treg% (SE) 4.74% (0.38) 3.22% (0.26) 0.02 5.97% (1.41) 2.82% (0.18) 0.11
Mean pDC% (SE) 0.07% (0.02) 0.09% (0.01) 0.12 0.05% (0.02) 0.15% (0.03) 0.02
HIV RNA level
Undetectable 3 (23%) 5 (50%) 0.22 NA NA
Detectable 10 (77%) 5 (50%) NA NA
HAART use in past 6 mo., No. (%)
No 6 (46.2) 3 (30.0) 0.67 NA NA
Yes 7 (53.9) 7 (70.0) NA NA
HAART, highly active anti-retroviral therapy; oncHPV, oncogenic HPV; Pdc, plasmacytoid dendritic cell; SD, standard deviation; SE,
standard error; Treg, regulatory T-cell.
*Significantly different between HIV-positive and HIV-negative persisters with p < 0.05.
aThe selection of HIV-positive women was limited to those with a CD4 count > 350 since it was felt that the impact of pDC% and Treg%
might be difficult to discern in women with a very low CD4 count. bAn oncHPV Persister was a priori defined as a subject who tested
positive for at least one oncHPV type at the time of blood collection and then continued to test positive for one or more of these exact
oncHPV types for ‡ 1.5 years. cAn oncHPV Clearer was a priori defined as a woman who tested positive for at least one oncHPV type at the
time of blood collection but had no oncHPV detected 6 months later, at the next clinic visit.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of serial oncHPV positivity with no available methods to
eradicate oncHPV infection. Furthermore, local Treg and
pDC immunotherapy might be useful as adjuvants to reduce
the risk of recurrent cervical neoplasia, especially in HIV-
positive and other high risk populations. It is also possible
that the relation of Tregs and pDCs with oncHPV persis-
tence may play a role in the beneficial effects of HAART in
reducing oncHPV persistence observed in prior studies
(1,2,12). Larger and more comprehensive studies are
therefore warranted to expand upon the current observa-
tions, and better understand the effects of pDCs and Tregs
on HPV natural history.
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